2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Bvf Partners L P/Il | — | 12,584,459 | Feb 13, 2023 |
| Biotechnology Value Fund L P | — | 12,584,459 | Feb 13, 2023 |
| Bvf I Gp Llc | — | 12,584,459 | Feb 13, 2023 |
| Biotechnology Value Fund II Lp | — | 12,584,459 | Feb 13, 2023 |
| Bvf II Gp Llc | — | 12,584,459 | Feb 13, 2023 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Mar 5, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sell | 22.5 | -11,826 | -5.45% | ✗ | $248.2K |
| Mar 3, 2026 | Mar 5, 2026 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Sell | 22.5 | -11,313 | -9.53% | ✗ | $237.5K |
| Mar 3, 2026 | Mar 5, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sell | 20.0 | -18,735 | -9.17% | ✗ | $393.2K |
| Mar 3, 2026 | Mar 5, 2026 | Yoon Jun | CFO | Sell | 30.0 | -22,305 | -0.78% | ✗ | $468.2K |
| Mar 3, 2026 | Mar 5, 2026 | Hall Ashley | Chief Development Officer | Sell | 22.5 | -4,836 | -4.31% | ✗ | $101.5K |
| Mar 3, 2026 | Mar 5, 2026 | Stevens Raymond C | CEO | Sell | 17.5 | -53,454 | -1.94% | ✗ | $1.1M |
| Jan 15, 2026 | Jan 20, 2026 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 8, 2025 | Dec 10, 2025 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Hall Ashley | Chief Development Officer | Sell | 26.3 | -6,021 | -5.09% | ✗ | $46.6K |
| Sep 18, 2025 | Sep 22, 2025 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sell | 22.5 | -8,106 | -3.60% | ✗ | $62.8K |
| Jul 1, 2025 | Aug 20, 2025 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Sell | 26.3 | -4,470 | -3.63% | ✗ | $30.6K |
| Jul 1, 2025 | Aug 20, 2025 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sell | 22.5 | -12,846 | -5.92% | ✗ | $87.8K |
| Jul 30, 2025 | Aug 1, 2025 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 1, 2025 | Jul 3, 2025 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sell | 78.8 | +5,325 | 2.42% | ✗ | $19.6K |
| Mar 1, 2025 | Jul 3, 2025 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Sell | 91.3 | +22,635 | 22.51% | ✗ | $14.4K |
| Mar 1, 2025 | Jul 3, 2025 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sell | 95.0 | +50,637 | 30.41% | ✗ | $51K |
| Mar 1, 2025 | Jul 3, 2025 | Yoon Jun | CFO | Sell | 72.5 | +26,577 | 0.93% | ✗ | $95.5K |
| Mar 1, 2025 | Jul 3, 2025 | Stevens Raymond C | CEO | Sell | 82.5 | +61,152 | 2.27% | ✗ | $208.6K |
| Jun 23, 2025 | Jun 25, 2025 | Russell Angus C. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2025 | Jun 25, 2025 | LOVE TED W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2025 | Jun 25, 2025 | Waldstreicher Joanne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2025 | Jun 25, 2025 | DOBMEIER ERIC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2025 | Jun 25, 2025 | TETLOW SHARON | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 23, 2025 | Jun 25, 2025 | WELCH DANIEL G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Coll Crespo Blas | Chief Medical Officer | Neutral | 90.0 | +116,988 | 114.02% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Hall Ashley | Chief Development Officer | Neutral | 90.0 | +51,048 | 75.86% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Neutral | 90.0 | +63,810 | 173.73% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Neutral | 90.0 | +80,829 | 94.31% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Yoon Jun | CFO | Neutral | 85.0 | +170,166 | 6.35% | ✗ | - |
| Mar 15, 2025 | Mar 18, 2025 | Stevens Raymond C | CEO | Neutral | 90.0 | +340,332 | 14.49% | ✗ | - |
| Feb 6, 2025 | Feb 10, 2025 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2024 | Sep 20, 2024 | Hall Ashley | Chief Development Officer | Neutral | 90.0 | +67,290 | 100.00% | ✗ | - |
| Sep 20, 2024 | Hall Ashley | Chief Development Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 18, 2024 | Sep 20, 2024 | Coll Crespo Blas | Chief Medical Officer | Neutral | 90.0 | +90,600 | 755.00% | ✗ | - |
| Sep 20, 2024 | Coll Crespo Blas | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 26, 2024 | Aug 28, 2024 | Russell Angus C. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 28, 2024 | Russell Angus C. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 25, 2024 | Jun 27, 2024 | LOVE TED W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2024 | Jun 27, 2024 | Waldstreicher Joanne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2024 | Jun 27, 2024 | DOBMEIER ERIC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2024 | Jun 27, 2024 | TETLOW SHARON | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2024 | Jun 27, 2024 | WELCH DANIEL G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2024 | Jun 14, 2024 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 10, 2024 | Jun 12, 2024 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2024 | Jun 5, 2024 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Neutral | 58.8 | - | 0.00% | ✓ | - |
| Apr 19, 2024 | FMR LLC | Other | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 15, 2024 | Mar 20, 2024 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2024 | Mar 20, 2024 | Bach Mark Allen | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2024 | Mar 20, 2024 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2024 | Mar 20, 2024 | Yoon Jun | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2024 | Mar 20, 2024 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 15, 2024 | Mar 19, 2024 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Neutral | 90.0 | +85,707 | 100.00% | ✗ | - |
| Mar 15, 2024 | Mar 19, 2024 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Neutral | 90.0 | +36,729 | 100.00% | ✗ | - |
| Mar 15, 2024 | Mar 19, 2024 | Bach Mark Allen | CHIEF MEDICAL OFFICER | Neutral | 90.0 | +26,235 | 100.00% | ✗ | - |
| Mar 15, 2024 | Mar 19, 2024 | Yoon Jun | CFO | Neutral | 77.5 | +59,469 | 2.27% | ✗ | - |
| Mar 15, 2024 | Mar 19, 2024 | Stevens Raymond C | CEO | Neutral | 85.0 | +134,682 | 5.14% | ✗ | - |
| Mar 14, 2024 | Mar 18, 2024 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 15, 2024 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 22, 2023 | Dec 27, 2023 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 5, 2023 | Dec 7, 2023 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 18, 2023 | Oct 23, 2023 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 12, 2023 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 3, 2023 | Aug 4, 2023 | WELCH DANIEL G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 3, 2023 | Aug 4, 2023 | LOVE TED W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 4, 2023 | LOVE TED W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 10, 2023 | May 12, 2023 | BVF PARTNERS L P/IL | 10% Owner | Neutral | 27.5 | -7,410,518 | -100.00% | ✗ | - |
| Feb 13, 2023 | BVF PARTNERS L P/IL | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 7, 2023 | Feb 9, 2023 | WELCH DANIEL G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | Farid Ramy | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | Jung Melita Sun | Chief Business Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | Bach Mark Allen | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | Yoon Jun | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | FMR LLC | Other | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 7, 2023 | Feb 9, 2023 | FIL Ltd | Other | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 2, 2023 | Feb 6, 2023 | Yoon Jun | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 2, 2023 | Feb 6, 2023 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 2, 2023 | Waldstreicher Joanne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | FIL Ltd | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | DOBMEIER ERIC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | TETLOW SHARON | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Farid Ramy | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | WELCH DANIEL G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Ma Yingli | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Jung Melita Sun | Chief Business Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Bach Mark Allen | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Lin Xichen | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | FMR LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Yoon Jun | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 2, 2023 | Stevens Raymond C | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |